IMMUNOTHERAPY OF MALIGNANT BRAIN TUMORS USING OK-432-ACTIVATED MONONUCLEAR CELLS COMBINED WITH HUMAN MONOCLONAL ANTIBODY AGAINST CANCER

点击翻译按钮获取中文摘要

Local administration of OK-432-activated killer (OK-AK) cells has been effective in most patients with malignant brain tumor. In this therapy natural killer(NK) cells are the main effector cells. Recently the inverse correlation between major histocompatibility (MHC) class I expression and susceptibility of target cells to NK cell-mediated lysis has been reported. We exmained the sensitivity of human glioblastoma cells under MHC class I-expressing and the non-expressing conditions.Our results showed that OK-AK cells exclusively lysed the human gliobalstoma cells and that the susceptibility of glioblastoma cells to NK lysis was markedly reduced by the expression of MHC class I antigens on their cell surface. Human monoclonal antibody against cancer (CLN-IgG) was bound to malignant gliomans more than to low-grade gliomas. The susceptibility of glioblastoma cells with the expression of MHC class I antigens to NK lysis was improved by the administration of CLN-IgG.The present results indicate that CLN-IgG may enhance the cytocidal effect of OK-AK cells against malignant gliomas.